Sphere Medical Holding Regulatory News (SPHR)

For Immediate Release 23 May 2014

Sphere Medical Holding plc

Issue of Equity

Cambridge, UK, 23 May 2014: Sphere Medical Holding plc (AIM: SPHR.L) ("Sphere Medical" or the "Company"), a leading developer of innovative monitoring and diagnostic products for the critical care setting, today announces that 196,630 ordinary shares of £0.01 each in the capital of the Company ("New Ordinary Shares") have been issued and allotted pursuant to the exercise of share options under the Enterprise Management Incentives Scheme by a former employee.

Application will be made to the London Stock Exchange for the 196,630 New Ordinary Shares to be admitted to trading on AIM ("Admission"), Admission is expected on 30 May 2014. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 59,405,290. Accordingly, the figure of 59,405,290 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Notes for Editors

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside. Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development of Proxima and enhancement of Sphere's operational and production capabilities in 2013.

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Johnson & Johnson Development Corporation. Other significant investors include Life Sciences Partners (LSP Life Sciences Fund).

For further information, please visit www.spheremedical.com